Skip to content

Study · Animal study (in vivo) · mouse · 2016

10 results

Preconditioning mice with activators of AMPK ameliorates ischemic acute kidney injury in vivo.

Lieberthal W, Tang M, Lusco M, Abate M, Levine JS

American journal of physiology. Renal physiology1 Jun 2016Cited by 27 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with ischemic kidney injury, AICAR preconditioning reduced renal dysfunction.

    In plain wordsIn mice, AICAR pretreatment reduced kidney dysfunction after ischemic injury.

    Outcome
    DecreaseRenal dysfunction
    Study

    mousen: not reported in source

    Ischemic acute kidney injury
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Finally, we demonstrate that preconditioning mice with AICAR or A-769662 substantially reduces the severity of renal dysfunction and tubular injury in a model of ischemic AKI in vivo and that the efficacy of AICAR and A-768662 in ameliorating ischemic AKI in vivo is comparable.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with ischemic kidney injury, AICAR preconditioning reduced tubular injury.

    In plain wordsIn mice, AICAR pretreatment reduced kidney tubular injury.

    Outcome
    DecreaseTubular injury
    Study

    mousen: not reported in source

    Ischemic acute kidney injury
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Finally, we demonstrate that preconditioning mice with AICAR or A-769662 substantially reduces the severity of renal dysfunction and tubular injury in a model of ischemic AKI in vivo and that the efficacy of AICAR and A-768662 in ameliorating ischemic AKI in vivo is comparable.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, AICAR and A-768662 showed comparable efficacy against ischemic acute kidney injury.

    In plain wordsIn mice, AICAR and A-768662 provided comparable protection against ischemic kidney injury.

    Outcome
    No significant changeComparative kidney protection
    Study

    mousen: not reported in source

    Ischemic acute kidney injury
    Comparator
    A-768662
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Finally, we demonstrate that preconditioning mice with AICAR or A-769662 substantially reduces the severity of renal dysfunction and tubular injury in a model of ischemic AKI in vivo and that the efficacy of AICAR and A-768662 in ameliorating ischemic AKI in vivo is comparable.
  4. 04LabIn vitro (cells)Mechanism

    In cultured proximal tubular cells, AICAR preconditioning reduced apoptosis from subsequent metabolic stress.

    In plain wordsIn cells, AICAR pretreatment reduced cell death from later metabolic stress.

    Outcome
    DecreaseStress-induced apoptosis
    Study

    n: not reported in source

    Cultured proximal tubular cells
    Outcome group
    Cell viability and death · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We demonstrate that preconditioning PTCs with 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) or A-769662 reduces apoptosis of PTCs induced by subsequent stress.
  5. 05LabIn vitro (cells)Mechanism

    In proximal tubular cells, AICAR was less effective than A-79662 for the reported cellular alterations.

    In plain wordsIn cells, AICAR produced weaker reported cellular alterations than A-79662.

    Outcome
    DecreaseRelative cellular response
    Study

    n: not reported in source

    Cultured proximal tubular cells
    Comparator
    A-79662
    Outcome group
    Receptor activity and mechanism · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We also provide entirely novel evidence that that A-79662 is substantially more effective than AICAR in mediating these alterations in PTCs in vitro.

Studies that did not test the peptide alone5

In this study, AICAR (acadesine) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking AICAR (acadesine).

  1. 06LabNot a test of AICAR (acadesine) aloneIn vitro (cells)Mechanism

    In proximal tubular cells, AMPK activator pretreatment, including AICAR, increased cytosolic ATP during metabolic stress.

    In plain wordsIn cells, AMPK activators, including AICAR, increased cellular ATP during metabolic stress.

    Outcome
    IncreaseCytosolic ATP
    Study

    n: not reported in source

    Cultured proximal tubular cells
    Outcome group
    Glycemic control · Kidney and urinary

    Source sentences

    Summary
    We also show that the reduction in cell death during metabolic stress associated with pretreatment by AMPK activators is associated with an increase in the cytosolic level of ATP, which is mediated by an increase in the rate of glycolysis.
    1 context sentence
    Summary · context
    We demonstrate that preconditioning PTCs with 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) or A-769662 reduces apoptosis of PTCs induced by subsequent stress.

    In this study, AICAR (acadesine) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking AICAR (acadesine).

  2. 07LabNot a test of AICAR (acadesine) aloneIn vitro (cells)Mechanism

    In proximal tubular cells, AMPK activators, including AICAR, increased glycolysis during metabolic stress.

    In plain wordsIn cells, AMPK activators, including AICAR, increased glycolysis during metabolic stress.

    Outcome
    IncreaseGlycolysis rate
    Study

    n: not reported in source

    Cultured proximal tubular cells
    Outcome group
    Glycemic control · Kidney and urinary

    Source sentences

    Summary
    We also show that the reduction in cell death during metabolic stress associated with pretreatment by AMPK activators is associated with an increase in the cytosolic level of ATP, which is mediated by an increase in the rate of glycolysis.
    1 context sentence
    Summary · context
    We demonstrate that preconditioning PTCs with 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) or A-769662 reduces apoptosis of PTCs induced by subsequent stress.

    In this study, AICAR (acadesine) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking AICAR (acadesine).

  3. 08LabNot a test of AICAR (acadesine) aloneIn vitro (cells)Mechanism

    In proximal tubular cells, AMPK activators, including AICAR, increased glucose uptake.

    In plain wordsIn cells, AMPK activators, including AICAR, increased glucose uptake.

    Outcome
    IncreaseGlucose uptake
    Study

    n: not reported in source

    Cultured proximal tubular cells
    Outcome group
    Glycemic control · Kidney and urinary

    Source sentences

    Summary
    In addition, we provide evidence that the effect of AMPK activators on glycolysis is mediated, at least in part, by an increased uptake of glucose, and by the induction of hexokinase II (HK II) expression.
    1 context sentence
    Summary · context
    We demonstrate that preconditioning PTCs with 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) or A-769662 reduces apoptosis of PTCs induced by subsequent stress.

    In this study, AICAR (acadesine) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking AICAR (acadesine).

  4. 09LabNot a test of AICAR (acadesine) aloneIn vitro (cells)Mechanism

    In proximal tubular cells, AMPK activators, including AICAR, induced hexokinase II expression.

    In plain wordsIn cells, AMPK activators, including AICAR, increased hexokinase II expression.

    Outcome
    IncreaseHexokinase II expression
    Study

    n: not reported in source

    Cultured proximal tubular cells
    Outcome group
    Receptor activity and mechanism · Kidney and urinary

    Source sentences

    Summary
    In addition, we provide evidence that the effect of AMPK activators on glycolysis is mediated, at least in part, by an increased uptake of glucose, and by the induction of hexokinase II (HK II) expression.
    1 context sentence
    Summary · context
    We demonstrate that preconditioning PTCs with 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) or A-769662 reduces apoptosis of PTCs induced by subsequent stress.

    In this study, AICAR (acadesine) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking AICAR (acadesine).

  5. 10LabNot a test of AICAR (acadesine) aloneIn vitro (cells)Mechanism

    In proximal tubular cells, AMPK activator-associated hexokinase II induction involved CREB phosphorylation.

    In plain wordsIn cells, AMPK activator treatment linked increased hexokinase II expression to CREB activation.

    Outcome
    IncreaseCREB phosphorylation
    Study

    n: not reported in source

    Cultured proximal tubular cells
    Outcome group
    Receptor activity and mechanism · Kidney and urinary

    Source sentences

    Summary
    Our data also show that the increased in HK II expression associated with preconditioning with AMPK activators is mediated by the activation (phosphorylation) of the cAMP-response element binding protein (CREB).
    1 context sentence
    Summary · context
    We demonstrate that preconditioning PTCs with 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) or A-769662 reduces apoptosis of PTCs induced by subsequent stress.

    In this study, AICAR (acadesine) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking AICAR (acadesine).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.